Aquestive Therapeutics, Inc. (AQST)
Free
No email, no account, no signup.
Pulling latest news for Aquestive Therapeutics, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Pharmaceuticals and drug delivery
Market Cap
$522M
We're already tracking Aquestive Therapeutics, Inc. — here are the latest events we've registered
Recent News
- In March 2025, the company initiated the New Drug Application filing process with the FDA for Anaphylm, a sublingual film for the treatment of anaphylaxis. A commercial launch is anticipated in the first quarter of 2026, pending regulatory approval. The company is scheduled to report its first quarter 2026 financial results on May 13, 2026.
Want to know how this news affects Aquestive Therapeutics, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Aquestive Therapeutics, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.